220 related articles for article (PubMed ID: 37049499)
1. Docosahexaenoic Acid, a Key Compound for Enhancing Sensitization to Drug in Doxorubicin-Resistant MCF-7 Cell Line.
Crovella S; Ouhtit A; Rahman SM; Rahman MM
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049499
[TBL] [Abstract][Full Text] [Related]
2. Docosahexaenoic Acid Incorporation Is Not Affected by Doxorubicin Chemotherapy in either Whole Cell or Lipid Raft Phospholipids of Breast Cancer Cells in vitro and Tumor Phospholipids in vivo.
Newell M; Patel D; Goruk S; Field CJ
Lipids; 2020 Sep; 55(5):549-565. PubMed ID: 32588470
[TBL] [Abstract][Full Text] [Related]
3. Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation.
Mahéo K; Vibet S; Steghens JP; Dartigeas C; Lehman M; Bougnoux P; Goré J
Free Radic Biol Med; 2005 Sep; 39(6):742-51. PubMed ID: 16109304
[TBL] [Abstract][Full Text] [Related]
4. DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA.
Rahman MM; Veigas JM; Williams PJ; Fernandes G
Breast Cancer Res Treat; 2013 Oct; 141(3):341-52. PubMed ID: 24062211
[TBL] [Abstract][Full Text] [Related]
5. Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine.
Fahrmann JF; Hardman WE
Lipids Health Dis; 2013 Mar; 12():36. PubMed ID: 23497075
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
7. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
8. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
9. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
10. Docosahexanoic acid improves chemotherapy efficacy by inducing CD95 translocation to lipid rafts in ER(-) breast cancer cells.
Ewaschuk JB; Newell M; Field CJ
Lipids; 2012 Nov; 47(11):1019-30. PubMed ID: 23054549
[TBL] [Abstract][Full Text] [Related]
11. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
[TBL] [Abstract][Full Text] [Related]
12. Docosahexaenoic acid monoglyceride induces apoptosis and autophagy in breast cancer cells via lipid peroxidation-mediated endoplasmic reticulum stress.
Wang TT; Yang Y; Wang F; Yang WG; Zhang JJ; Zou ZQ
J Food Sci; 2021 Oct; 86(10):4704-4716. PubMed ID: 34494660
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
14. Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation.
Kang KS; Wang P; Yamabe N; Fukui M; Jay T; Zhu BT
PLoS One; 2010 Apr; 5(4):e10296. PubMed ID: 20421971
[TBL] [Abstract][Full Text] [Related]
15. Treatment with DHA Modifies the Response of MDA-MB-231 Breast Cancer Cells and Tumors from nu/nu Mice to Doxorubicin through Apoptosis and Cell Cycle Arrest.
Newell M; Brun M; Field CJ
J Nutr; 2019 Jan; 149(1):46-56. PubMed ID: 30601995
[TBL] [Abstract][Full Text] [Related]
16. Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines.
Liu QY; Tan BK
Life Sci; 2000; 67(10):1207-18. PubMed ID: 10954054
[TBL] [Abstract][Full Text] [Related]
17. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
18. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
19. Lipid-based nanocarriers co-loaded with artemether and triglycerides of docosahexaenoic acid: Effects on human breast cancer cells.
Lanna EG; Siqueira RP; Machado MGC; de Souza A; Trindade IC; Branquinho RT; Mosqueira VCF
Biomed Pharmacother; 2021 Feb; 134():111114. PubMed ID: 33352447
[TBL] [Abstract][Full Text] [Related]
20. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells.
Mussi SV; Sawant R; Perche F; Oliveira MC; Azevedo RB; Ferreira LA; Torchilin VP
Pharm Res; 2014 Aug; 31(8):1882-92. PubMed ID: 24522814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]